Gibran, an AI research startup, has secured $2.6 million in seed funding from Together Fund to develop models using small ...

Hiding in Plain Sight Quantum computing has surged from theoretical curiosity to a transformative frontier, promising to ...

Quantum computing has rapidly advanced in recent years due to substantial development in both hardware and algorithms. These advances are carrying quantum computers closer to their impending ...

Benchmark analyst David Williams reiterated his Buy rating on IonQ and stuck with a solid $50 price target, implying a 25% ...

1 Department of Pharmaceutical Sciences, College of Pharmacy, Howard University, Washington, D.C., United States 2 Artificial Intelligence and Drug Discovery (AIDD) Core Laboratory for District of ...

Fun fact: James Webb Space Telescope’s exoplanet discovery While the new study marks the first time the James Webb Space Telescope has discovered a new exoplanet through direct imaging, the ...

Oak Brook, IL – Volume 33 of SLAS Discovery features one review, three original research articles and one entry in the upcoming Special Issue on Biomolecular Condensates as Targets for Drug Discovery.

VK2375 is a dual GLP-1/GIP receptor agonist similar to Eli Lilly 's blockbuster weight loss drug Zepbound. Viking is developing VK2375 in both subcutaneous (under the skin) and oral formulations.

Biomarkers can stratify patient populations or quantify drug benefit in primary prevention or disease-modification studies in poorly served areas such as neurodegeneration and cancer.

Drug discovery has traditionally been slow, expensive and prone to failure, but AI and machine learning are set to change all that.